Skip to main content

Health economic modeling for medical technologies in Europe

Early and comprehensive economic models to determine economic value proposition and inform healthcare decision-makers

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

New HTAs initiated in Poland

In early August 2023, the Polish Agency for Health Technology Assessment and Tariff System (AOTMiT) announced the start of the evaluation of several technologies in men’s health, neuromodulation and in-vitro diagnostics fields.

On August 3, 2023, the AOTMiT initiated the evaluation of the conditions for the provision, as well as preparation of the evaluation of the implantation, insertion, placement, or relocation of an intracranial brain neurostimulator in Parkinson's disease. In January 2023, the President of the AOTMiT requested the healthcare facilities (n=20) providing the implantation, insertion, placement, or relocation of an intracranial brain neurostimulator in the treatment of Parkinson's disease to provide cost data for the procedure to suggest the reimbursement amount for the service.

Also, on August 3, 2023, the preparation of analytical materials concerning the introduction of a model for implementing the fecal immunochemical (FiT) test into the health care system was initiated by the AOTMiT.

Finally, on August 4, 2023, AOTMiT initiated the preparation of a review of scientific reports concerning the technologies used in prostate cancer prevention.

The full details in Polish can be found here, here, and here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.